First, SGLT2 inhibitors consistently lowered blood urate levels in large randomized clinical trials.15,16,17 Hyperuricemia appears to be the main risk factor for gout; therefore, baseline hyperuricemia18 or posttreatment blood urate levels19 have been shown to predict gout occurrence. This evidence concerns the gene SLC5A2 and hyperuricemia.